Adjuvant chemotherapy in nasopharyngeal carcinoma
- PMID: 37290469
- DOI: 10.1016/S1470-2045(23)00266-8
Adjuvant chemotherapy in nasopharyngeal carcinoma
Conflict of interest statement
MLKC reports personal fees from Astellas, Janssen, Bayer, Pfizer, BeiGene, MSD, Varian, IQVIA, Telix Pharmaceuticals; personal fees and non-financial support from AstraZeneca; non-financial support from Decipher Biosciences and MedLever; consulting fees from immunoSCAPE; is a co-inventor of the patent of a High Sensitivity Lateral Flow Immunoassay For Detection of Analyte in Sample (10202107837T), Singapore; and serves on the Board of Directors of Digital Life Line that owns the licensing agreement of the patent, outside the submitted work. MLKC is supported by the National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSAINV20nov-0021), the Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme, NCCS Cancer Fund, and the Kua Hong Pak Head and Neck Cancer Research Programme. All other authors declare no competing interests.
Comment on
-
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2023 Jul;24(7):798-810. doi: 10.1016/S1470-2045(23)00232-2. Epub 2023 Jun 5. Lancet Oncol. 2023. PMID: 37290468 Clinical Trial.
Similar articles
-
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma-Is This the New Standard of Care?JAMA Oncol. 2022 May 1;8(5):715-716. doi: 10.1001/jamaoncol.2022.0082. JAMA Oncol. 2022. PMID: 35323867 No abstract available.
-
Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.Invest New Drugs. 2021 Apr;39(2):564-570. doi: 10.1007/s10637-020-00999-y. Epub 2020 Sep 17. Invest New Drugs. 2021. PMID: 32940872
-
Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.Jpn J Clin Oncol. 2017 Aug 1;47(8):705-712. doi: 10.1093/jjco/hyx057. Jpn J Clin Oncol. 2017. PMID: 28431119
-
Progress and controversy for the role of chemotherapy in nasopharyngeal carcinoma.Jpn J Clin Oncol. 2015 Mar;45(3):244-7. doi: 10.1093/jjco/hyu212. Epub 2015 Jan 12. Jpn J Clin Oncol. 2015. PMID: 25583421 Review.
-
Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies.Hematol Oncol Clin North Am. 2015 Dec;29(6):1107-22. doi: 10.1016/j.hoc.2015.07.004. Epub 2015 Oct 20. Hematol Oncol Clin North Am. 2015. PMID: 26568551 Review.
Cited by
-
Lactate-related gene signatures as prognostic predictors and comprehensive analysis of immune profiles in nasopharyngeal carcinoma.J Transl Med. 2024 Dec 20;22(1):1116. doi: 10.1186/s12967-024-05935-9. J Transl Med. 2024. PMID: 39707377 Free PMC article.
-
Uncovering the molecular mechanisms of Qingdu Zengye Decoction in the treatment of nasopharyngeal carcinoma: an integrative investigation.Front Pharmacol. 2025 Jul 17;16:1648294. doi: 10.3389/fphar.2025.1648294. eCollection 2025. Front Pharmacol. 2025. PMID: 40746726 Free PMC article.
-
Prognostic value of the fibrinogen albumin ratio index (FARI) in nasopharyngeal carcinoma patients undergoing radiotherapy.Sci Rep. 2023 Nov 23;13(1):20630. doi: 10.1038/s41598-023-48029-0. Sci Rep. 2023. PMID: 37996660 Free PMC article.
-
Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.Br J Cancer. 2025 Jul;133(1):85-93. doi: 10.1038/s41416-025-03033-1. Epub 2025 May 6. Br J Cancer. 2025. PMID: 40328916 Free PMC article.
-
Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer.Pharmaceutics. 2025 Jan 3;17(1):52. doi: 10.3390/pharmaceutics17010052. Pharmaceutics. 2025. PMID: 39861700 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources